JP2021512604A5 - - Google Patents

Info

Publication number
JP2021512604A5
JP2021512604A5 JP2020541938A JP2020541938A JP2021512604A5 JP 2021512604 A5 JP2021512604 A5 JP 2021512604A5 JP 2020541938 A JP2020541938 A JP 2020541938A JP 2020541938 A JP2020541938 A JP 2020541938A JP 2021512604 A5 JP2021512604 A5 JP 2021512604A5
Authority
JP
Japan
Prior art keywords
antibody
seq
antigen
acid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020541938A
Other languages
English (en)
Japanese (ja)
Other versions
JP7539834B2 (ja
JP2021512604A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/016430 external-priority patent/WO2019152895A1/en
Publication of JP2021512604A publication Critical patent/JP2021512604A/ja
Publication of JP2021512604A5 publication Critical patent/JP2021512604A5/ja
Priority to JP2024083146A priority Critical patent/JP2024119840A/ja
Application granted granted Critical
Publication of JP7539834B2 publication Critical patent/JP7539834B2/ja
Priority to JP2025245658A priority patent/JP2026048820A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020541938A 2018-02-01 2019-02-01 ガレクチン-3に対する抗体及びその使用方法 Active JP7539834B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024083146A JP2024119840A (ja) 2018-02-01 2024-05-22 ガレクチン-3に対する抗体及びその使用方法
JP2025245658A JP2026048820A (ja) 2018-02-01 2025-12-11 ガレクチン-3に対する抗体及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862625166P 2018-02-01 2018-02-01
US62/625,166 2018-02-01
PCT/US2019/016430 WO2019152895A1 (en) 2018-02-01 2019-02-01 Antibodies to galectin-3 and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024083146A Division JP2024119840A (ja) 2018-02-01 2024-05-22 ガレクチン-3に対する抗体及びその使用方法

Publications (3)

Publication Number Publication Date
JP2021512604A JP2021512604A (ja) 2021-05-20
JP2021512604A5 true JP2021512604A5 (OSRAM) 2022-02-24
JP7539834B2 JP7539834B2 (ja) 2024-08-26

Family

ID=67479885

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020541938A Active JP7539834B2 (ja) 2018-02-01 2019-02-01 ガレクチン-3に対する抗体及びその使用方法
JP2024083146A Pending JP2024119840A (ja) 2018-02-01 2024-05-22 ガレクチン-3に対する抗体及びその使用方法
JP2025245658A Pending JP2026048820A (ja) 2018-02-01 2025-12-11 ガレクチン-3に対する抗体及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024083146A Pending JP2024119840A (ja) 2018-02-01 2024-05-22 ガレクチン-3に対する抗体及びその使用方法
JP2025245658A Pending JP2026048820A (ja) 2018-02-01 2025-12-11 ガレクチン-3に対する抗体及びその使用方法

Country Status (6)

Country Link
US (2) US12180285B2 (OSRAM)
EP (1) EP3746123A4 (OSRAM)
JP (3) JP7539834B2 (OSRAM)
AU (1) AU2019215202B2 (OSRAM)
CA (1) CA3089988A1 (OSRAM)
WO (1) WO2019152895A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
JP7835441B2 (ja) * 2019-12-06 2026-03-25 トゥルーバインディング,インコーポレイテッド Gal3とインスリン受容体又はインテグリンとの相互作用を妨害する抗体及びそれらの使用方法
IL294486A (en) * 2020-01-13 2022-09-01 Truebinding Inc Antibodies against gal3 and methods of use
CN116157151A (zh) * 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
CN112062832B (zh) * 2020-09-24 2021-08-03 河南赛诺特生物技术有限公司 Galectin-3抗原表位肽、抗原、抗体、杂交瘤细胞株及试剂盒
JP7825633B2 (ja) * 2020-12-08 2026-03-06 メモリアル スローン ケタリング キャンサー センター ガレクチン-3に対する抗体及びその使用方法
CN115746134A (zh) * 2021-10-15 2023-03-07 深圳市睿盟创新生物科技有限公司 半乳糖凝集素-3的免疫测定

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851A (en) 1848-10-17 Machinery for doubling and twisting tarn
US198A (en) 1837-05-15 Mode of constructing boats for canals
US5569A (en) 1848-05-16 Corn-sheller
US825A (en) 1838-07-09 Bail way cooking-stove
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2374910A1 (fr) 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
US4824659A (en) 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988001213A1 (en) 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
GEP20033082B (en) 1991-03-15 2003-10-27 Amgen Inc Pegylation of Polypeptides
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
WO1993000951A1 (en) 1991-07-02 1993-01-21 Inhale, Inc. Method and device for delivering aerosolized medicaments
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU4829593A (en) 1992-09-23 1994-04-12 Fisons Plc Inhalation device
DE69322789T2 (de) 1992-10-19 1999-07-01 Dura Pharmaceuticals, Inc., San Diego, Calif. Trockenpulverinhalator
US5643252A (en) 1992-10-28 1997-07-01 Venisect, Inc. Laser perforator
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US5849695A (en) 1993-01-13 1998-12-15 The Regents Of The University Of California Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
DE69414369T2 (de) 1993-01-19 1999-05-27 Glaxo Group Ltd., Greenford, Middlesex Aerosol-spender und verfahren zu seiner herstellung
EP1978095A1 (en) 1993-02-12 2008-10-08 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptor proteins for controlling signal transduction and ligands binding thereto
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1997014719A1 (en) 1995-10-16 1997-04-24 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
GB9526100D0 (en) 1995-12-20 1996-02-21 Intersurgical Ltd Nebulizer
NZ324374A (en) 1996-01-03 1999-06-29 Glaxo Group Ltd Inhalation device
US6027947A (en) 1996-08-20 2000-02-22 Ramtron International Corporation Partially or completely encapsulated top electrode of a ferroelectric capacitor
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US5879681A (en) 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US5921447A (en) 1997-02-13 1999-07-13 Glaxo Wellcome Inc. Flow-through metered aerosol dispensing apparatus and method of use thereof
TR199902553T2 (xx) 1997-04-14 2000-03-21 Micromet Gesellschaft F�R Biomedizinische Forschung Mbh �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�.
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP1073464B1 (en) 1998-04-28 2004-10-06 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
WO2001044301A1 (en) 1999-11-29 2001-06-21 Unilever Plc Immobilized single domain antigen-binding molecules
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US20050032673A1 (en) * 2002-06-10 2005-02-10 John Constance M. Sustained release N-terminally truncated galectin-3 and antibodies to galectin-3 carbohydrate ligands for use in treating disease
JP2006522163A (ja) 2003-04-07 2006-09-28 グリコジェネシス, インク. ガレクチンアンタゴニストの組成物と使用
JP2007528723A (ja) 2003-08-22 2007-10-18 メディミューン,インコーポレーテッド 抗体のヒト化
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
WO2010039900A2 (en) 2008-09-30 2010-04-08 Aliva Biopharmaceuticals, Inc. Non-human mammals for the production of chimeric antibodies
LT2975051T (lt) 2009-06-26 2021-07-12 Regeneron Pharmaceuticals, Inc. Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
PL3251503T3 (pl) 2010-03-31 2024-07-08 Ablexis, Llc Modyfikacja myszy metodami inżynierii genetycznej w celu wytworzenia przeciwciał chimerycznych
ES2961381T3 (es) 2010-06-19 2024-03-11 Memorial Sloan Kettering Cancer Center Anticuerpos anti-GD2
WO2011163198A2 (en) * 2010-06-21 2011-12-29 Board Of Regents, The University Of Texas System Tg2 inhibitors and uses thereof
WO2014089267A1 (en) * 2012-12-05 2014-06-12 Eleven Biotherapeutics, Inc. Galectin-3 fusion proteins
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CA2979976A1 (en) * 2015-03-17 2016-09-22 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof
CN107383192B (zh) * 2017-07-19 2018-08-24 深圳市倍诺博生物科技有限公司 半乳糖凝集素-3检测试剂盒
EP3658172A4 (en) * 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
EP3466975A1 (en) * 2017-10-05 2019-04-10 Laboratoire Français du Fractionnement et des Biotechnologies A specific binding molecule directed against galectin-3 protein

Similar Documents

Publication Publication Date Title
JP7461950B2 (ja) Cd3抗体およびその医薬用途
TWI805121B (zh) 抗SIRPα抗體及其用途
JP2024501581A5 (OSRAM)
JP2019519492A5 (OSRAM)
CN112969476B (zh) 多特异性蛋白分子
JP2019524693A5 (OSRAM)
JP2019536470A5 (OSRAM)
KR20180089497A (ko) Fc 수용체-유사 5를 표적화하는 항체 및 사용 방법
JP2018504890A (ja) Gタンパク質共役受容体を標的化する抗体および使用の方法
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
CN114641504A (zh) 抗b7h4抗体及其双抗和应用
WO2024175093A1 (en) Antibodies, antigen-binding fragments and methods of use
JP2020502233A5 (OSRAM)
JP2022513050A5 (OSRAM)
KR20240164815A (ko) 항-tigit/항-pvrig 이중특이적 항체, 이의 약제학적 조성물 및 이의 용도
US20240309099A1 (en) Bispecific tetravalent antibody targeting egfr and her3
WO2023186063A1 (zh) 抗pvrig抗体、其药物组合物及用途
JP2021529524A5 (OSRAM)
RU2025109828A (ru) Антитела против b7h3 и способы их применения
TW202432593A (zh) 抗體、其抗原結合片段及其藥物用途
WO2025206223A1 (ja) 抗ヒトクローディン18.2抗体及びその使用
WO2025117872A1 (en) Bispecific antibody-like protein and methods of making and using thereof
HK40076375A (en) ANTI-SIRPα ANTIBODY AND APPLICATION THEREOF
IL321672A (en) Anti-pdl1/vegf antibodies and methods of use
IL321674A (en) Anti-cd47 antibodies and methods of use